Glycomet-GP 1 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 1mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to release insulin, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake by muscle cells. The combination of these two agents provides complementary mechanisms to achieve better glycemic control in patients inadequately managed by diet, exercise, and monotherapy. Glycomet-GP 1 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications. It is important to monitor blood glucose levels regularly to adjust dosage and minimize the risk of hypoglycemia, especially in patients with renal impairment or other comorbid conditions. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, primarily attributed to Metformin, while Glimepiride may cause hypoglycemia and weight gain. This medication should be used cautiously in patients with hepatic or renal dysfunction and is contraindicated in cases of diabetic ketoacidosis or severe renal impairment. Regular follow-up and laboratory monitoring are essential to ensure safety and efficacy during treatment with Glycomet-GP 1 Tablet PR.